There are 2934 resources available
Biomarker in RCC: Clinical perspective
Presenter: Toni Choueiri
Session: Frontline in mRCC: Ready to select treatment?
Resources:
Slides
Webcast
Introduction
Presenter: Iain Hagan
Session: Innate immune system and anti-mitotic agents: Two fields getting together
Resources:
Slides
Webcast
Chromosome mis-segregation in cancer
Presenter: Hiro Funabiki
Session: Innate immune system and anti-mitotic agents: Two fields getting together
Resources:
Slides
Webcast
TGFb and PD1: The relevance of tumour associated macrophages
Presenter: Thomas Powles
Session: Innate immune system and anti-mitotic agents: Two fields getting together
Resources:
Slides
Webcast
Cytoplasmic DNA and c-GAS STING signalling
Presenter: Joan Seoane
Session: Innate immune system and anti-mitotic agents: Two fields getting together
Resources:
Slides
Webcast
Conclusions and perspectives
Presenter: Joan Seoane
Session: Innate immune system and anti-mitotic agents: Two fields getting together
Resources:
Slides
Webcast
2560 - BAROCCO: A randomized phase II study of weekly paclitaxel vs. cediranib-olaparib combination given with continuous or intermittent schedule in patients with recurrent platinum resistant ovarian cancer (PROC)
Presenter: Nicoletta Colombo
Session: Proffered Paper 1 – Gynaecological cancers
Resources:
Abstract
Slides
Webcast
6602 - Phase 1B/2 Study of AVB500 (High Affinity Inhibitor of GAS6/AXL Path) in Combination with PAC and PLD in Platinum Resistant Recurrent Ovarian Cancer
Presenter: Bradley Monk
Session: Proffered Paper 1 – Gynaecological cancers
Resources:
Abstract
Slides
Webcast
1547 - Randomized Phase 2 (RP2) Study of ATR inhibitor M6620 in Combination with Gemcitabine versus Gemcitabine alone in Platinum-Resistant High Grade Serous Ovarian Cancer (HGSOC)
Presenter: Panagiotis Konstantinopoulos
Session: Proffered Paper 1 – Gynaecological cancers
Resources:
Abstract
Slides
Webcast
6256 - IMpower110: Interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD-L1–selected NSCLC
Presenter: David Spigel
Session: Proffered Paper 1 - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast